AUGUST 10, 2026 INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements about revenue growth through channel stuffing and undisclosed related party transactions. A Culper Research report claimed ADMA's reported 20% growth in 2025 was actually -3% when adjusted for extended payment terms. The stock declined over 16% following the report, and another 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.